• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

钠-葡萄糖共转运蛋白 2（SGLT2）抑制剂在肾结石中的应用：我们是否应该给肾结石患者使用“格列净”？

Sodium-glucose cotranspor ter 2 (SGLT2) inhibitors in nephrolithiasis: should we "gliflozin" patients with kidney stone disease?

机构信息

Pontifícia Universidade Católica do Paraná, Faculdade de Medicina, Curitiba, Paraná, Brazil.

Universidade Federal do Paraná, Departamento de Clínica Médica, Curitiba, Paraná, Brazil.

出版信息

J Bras Nefrol. 2024 Jul-Sep;46(3):e20230146. doi: 10.1590/2175-8239-JBN-2023-0146en.

DOI:10.1590/2175-8239-JBN-2023-0146en
PMID:38498673
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11287977/
Abstract

The prevalence of nephrolithiasis is increasing worldwide. Despite advances in understanding the pathogenesis of lithiasis, few studies have demonstrated that specific clinical interventions reduce the recurrence of nephrolithiasis. The aim of this review is to analyze the current data and potential effects of iSGLT2 in lithogenesis and try to answer the question: Should we also "gliflozin" our patients with kidney stone disease?

摘要

肾结石的患病率在全球范围内呈上升趋势。尽管人们对结石病的发病机制有了更多的了解，但很少有研究表明特定的临床干预可以降低肾结石的复发率。本文旨在分析目前 iSGLT2 在结石形成中的数据和潜在影响，并尝试回答以下问题：我们是否也应该对肾结石患者使用“格列净”类药物？

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4908/11287977/e6e486c0fb21/2175-8239-jbn-46-3-e20230146-gf02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4908/11287977/ecb074285a6f/2175-8239-jbn-46-3-e20230146-gf01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4908/11287977/e6e486c0fb21/2175-8239-jbn-46-3-e20230146-gf02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4908/11287977/ecb074285a6f/2175-8239-jbn-46-3-e20230146-gf01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4908/11287977/e6e486c0fb21/2175-8239-jbn-46-3-e20230146-gf02.jpg

相似文献

1
Sodium-glucose cotranspor ter 2 (SGLT2) inhibitors in nephrolithiasis: should we "gliflozin" patients with kidney stone disease?钠-葡萄糖共转运蛋白 2（SGLT2）抑制剂在肾结石中的应用：我们是否应该给肾结石患者使用“格列净”？
J Bras Nefrol. 2024 Jul-Sep;46(3):e20230146. doi: 10.1590/2175-8239-JBN-2023-0146en.
2
Inhibition of sodium-glucose cotransporter 2 suppresses renal stone formation.抑制钠-葡萄糖共转运蛋白 2 可抑制肾结石形成。
Pharmacol Res. 2022 Dec;186:106524. doi: 10.1016/j.phrs.2022.106524. Epub 2022 Oct 28.
3
Empagliflozin and Decreased Risk of Nephrolithiasis: A Potential New Role for SGLT2 Inhibition?恩格列净与肾结石风险降低：SGLT2 抑制的潜在新作用？
J Clin Endocrinol Metab. 2022 Jun 16;107(7):e3003-e3007. doi: 10.1210/clinem/dgac154.
4
Nephrolithiasis and sodium-glucose co-transporter-2 (SGLT-2) inhibitors: A meta-analysis of randomized controlled trials.肾结石病和钠-葡萄糖协同转运蛋白-2（SGLT-2）抑制剂：随机对照试验的荟萃分析。
Diabetes Res Clin Pract. 2019 Sep;155:107808. doi: 10.1016/j.diabres.2019.107808. Epub 2019 Aug 8.
5
Sodium-glucose cotransporter 2 inhibitors and risk of nephrolithiasis.钠-葡萄糖共转运蛋白 2 抑制剂与肾结石风险。
Diabetologia. 2021 Jul;64(7):1563-1571. doi: 10.1007/s00125-021-05424-4. Epub 2021 Mar 13.
6
Renal Protection with SGLT2 Inhibitors: Effects in Acute and Chronic Kidney Disease.SGLT2 抑制剂对肾脏的保护作用：在急性和慢性肾脏病中的作用。
Curr Diab Rep. 2022 Jan;22(1):39-52. doi: 10.1007/s11892-021-01442-z. Epub 2022 Feb 3.
7
Renal and Cardiac Implications of Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors: The State of the Science.钠-葡萄糖共转运蛋白 2（SGLT2）抑制剂的肾脏和心脏影响：科学现状。
Ann Pharmacother. 2018 Dec;52(12):1238-1249. doi: 10.1177/1060028018783661. Epub 2018 Jun 17.
8
Techniques to Assess the Effect of Sodium-Glucose Cotransporter 2 Inhibitors on Blood Volume in Patients with Diabetic Kidney Disease.评估钠-葡萄糖共转运蛋白 2 抑制剂对糖尿病肾病患者血容量影响的技术。
Nephron. 2024;148(3):137-142. doi: 10.1159/000534396. Epub 2023 Oct 9.
9
SGLT2 Inhibition for the Prevention and Treatment of Diabetic Kidney Disease: A Review.SGLT2 抑制剂在糖尿病肾病防治中的应用：综述
Am J Kidney Dis. 2018 Aug;72(2):267-277. doi: 10.1053/j.ajkd.2018.03.022. Epub 2018 Jun 14.
10
Renal Effects of Sodium-Glucose Co-Transporter Inhibitors.钠-葡萄糖协同转运蛋白抑制剂的肾脏作用。
Am J Cardiol. 2019 Dec 15;124 Suppl 1(Suppl 1):S28-S35. doi: 10.1016/j.amjcard.2019.10.027.

引用本文的文献

1
Brazilian Guidelines on evaluation and clinical management of Nephrolithiasis: Brazilian Society of Nephrology.巴西肾结石评估与临床管理指南：巴西肾脏病学会
J Bras Nefrol. 2025 Apr-Jun;47(2):e20240189. doi: 10.1590/2175-8239-JBN-2024-0189en.

本文引用的文献

1
SGLT2 Inhibitors: A New Therapeutical Strategy to Improve Clinical Outcomes in Patients with Chronic Kidney Diseases.SGLT2 抑制剂：改善慢性肾脏病患者临床结局的新治疗策略。
Int J Mol Sci. 2023 May 13;24(10):8732. doi: 10.3390/ijms24108732.
2
Impact of Sodium-Glucose Cotransporter-2 Inhibitors on Urolithiasis.钠-葡萄糖协同转运蛋白2抑制剂对尿路结石的影响。
Kidney Int Rep. 2023 Feb 3;8(4):925-928. doi: 10.1016/j.ekir.2023.01.034. eCollection 2023 Apr.
3
SGLT2 Inhibitors: The Sweet Success for Kidneys.钠-葡萄糖协同转运蛋白2抑制剂：肾脏的甜蜜成功
Annu Rev Med. 2023 Jan 27;74:369-384. doi: 10.1146/annurev-med-042921-102135.
4
Prescribing SGLT2 Inhibitors in Patients With CKD: Expanding Indications and Practical Considerations.为慢性肾脏病患者开具钠-葡萄糖协同转运蛋白2抑制剂：适应证拓展与实际考量
Kidney Int Rep. 2022 Aug 28;7(11):2546-2547. doi: 10.1016/j.ekir.2022.08.016. eCollection 2022 Nov.
5
Inhibition of sodium-glucose cotransporter 2 suppresses renal stone formation.抑制钠-葡萄糖共转运蛋白 2 可抑制肾结石形成。
Pharmacol Res. 2022 Dec;186:106524. doi: 10.1016/j.phrs.2022.106524. Epub 2022 Oct 28.
6
Empagliflozin in Patients with Chronic Kidney Disease.恩格列净在慢性肾脏病患者中的应用。
N Engl J Med. 2023 Jan 12;388(2):117-127. doi: 10.1056/NEJMoa2204233. Epub 2022 Nov 4.
7
Empagliflozin Changes Urine Supersaturation by Decreasing pH and Increasing Citrate.恩格列净通过降低 pH 值和增加柠檬酸盐来改变尿液过饱和度。
J Am Soc Nephrol. 2022 Jun;33(6):1073-1075. doi: 10.1681/ASN.2021111515. Epub 2022 Apr 6.
8
Empagliflozin and Decreased Risk of Nephrolithiasis: A Potential New Role for SGLT2 Inhibition?恩格列净与肾结石风险降低：SGLT2 抑制的潜在新作用？
J Clin Endocrinol Metab. 2022 Jun 16;107(7):e3003-e3007. doi: 10.1210/clinem/dgac154.
9
Impact of the SGLT2 inhibitor empagliflozin on urinary supersaturations in kidney stone formers (SWEETSTONE trial): protocol for a randomised, double-blind, placebo-controlled cross-over trial.恩格列净对肾结石形成者尿液过饱和度的影响（SWEETSTONE 试验）：一项随机、双盲、安慰剂对照交叉试验的方案。
BMJ Open. 2022 Mar 14;12(3):e059073. doi: 10.1136/bmjopen-2021-059073.
10
Sodium-glucose cotransporter 2 inhibitors and risk of nephrolithiasis.钠-葡萄糖共转运蛋白 2 抑制剂与肾结石风险。
Diabetologia. 2021 Jul;64(7):1563-1571. doi: 10.1007/s00125-021-05424-4. Epub 2021 Mar 13.